Wire · opportunities
Novo Nordisk to launch cheaper Ozempic copy in South Africa
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 July 2026 · Fusion42 review
Novo Nordisk is launching Extensior, a cheaper semaglutide copy, in South Africa to expand access to GLP-1 treatment for type 2 diabetes patients. The move signals a producer's own-brand generic strategy to capture price-sensitive emerging markets.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
The GLP-1 incumbents are now cannibalising their own premium products in price-sensitive markets. If you're building cheaper diabetes or weight management tools for emerging markets, you're competing against Novo Nordisk's own discounted Ozempic—not against Novo Nordisk's pricing power.
◆ Coverage
1 source · 20 Jul 2026
◆ Related on Wire
◆ Topics